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Abstract 
Background: Lipoprotein‑related mechanisms have been associated with damage to the cardiovascular system in 
diabetic patients. Apolipoprotein E gene which affects the clearance of lipoproteins and consequently the lipid profile 
in our body is one of the most studied candidate genes and recently has been reported to be associated with T2DM 
and CAD. In this work, we studied the association of apoE gene polymorphism with T2DM and CVD and its effect on 
plasma lipids profile.
Methods: Our study was conducted on 284 subjects categorized into 100 patients with T2DM, 100 patients with 
T2DM complicated with CVD and 84 normal control subjects. ApoE gene polymorphism was genotyped by real‑time 
PCR using TaqMan® SNP Genotyping Assay.
Results: ApoE E3/E3 genotype was the most common in our subjects. The frequencies of E3/E4 genotype and ε4 
allele were increased in both T2DM patients and CVD patients as compared with controls, but were significant only 
in CVD patients (p = 0.004 and 0.007, respectively). Diabetic patients who carried E3/E4 genotype were at 2.4‑fold 
increased risk to develop CVD (95 % CI 1.14–5.19, P = 0.02) and the ε4 allele associated with 2.23‑fold higher CVD risk 
(95 % CI 1.09–4.59, P = 0.02). After adjustment for other established risk factors, E3/E4 genotype was an independent 
risk factor for CVD (OR = 2.3, p = 0.009) but not for T2DM (OR = 1.7, p = 0.28), while ε4 allele was an independent risk 
factor for both T2DM (OR = 2.2, p = 0.04) and CVD (OR = 3.0, p = 0.018) with 5.9‑fold increased risk to develop CVD 
in T2DM patients (p = 0.019). E3/E4 genotype associated with significantly higher levels of TC and non HDL‑C in all 
groups and with significantly higher levels of LDL‑C in both T2DM and CVD patients.
Conclusions: ApoE gene polymorphisms associate with CVD and affect the lipid profile. The ε4 allele is an independ‑
ent risk factor for both T2DM and CVD. Further genetic studies to add information beyond the traditional cardiovascu‑
lar risk factors in T2DM and to identify risk genotypes will help in early prediction and identification of at risk patients.
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Background
Type 2 diabetes mellitus (T2DM) is one of the most 
common diseases with a high incidence and prevalence 
throughout the world [1]. The prevalence of type 2 dia-
betes is rising at an alarming rate due to increase in life 
expectancy, obesity, physical inactivity and adoption of 
sedentary lifestyles [2]. In 2013, the International Dia-
betes Federation (IDF) estimated that almost 366  mil-
lion people (8.3  % of the adult population) around the 
world have diabetes, and 280 million people (6.4 % of the 
adult population) have impaired glucose tolerance (IGT), 
a major risk factor for type 2 diabetes. By 2030, these 
figures are expected to rise to 552 million (9.9  % of the 
world’s population) and 398 million (7.1  % of the adult 
population), respectively. In developing countries, the 
number of people with diabetes will increase by 150 % in 
the next 25  years [3]. Egypt is in the world 8th place in 
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terms of diabetes incidence, affecting up to 9.3 % of pop-
ulation, and due to a rapidly increasing and ageing popu-
lation, Egypt will have the highest projected number of 
people with diabetes in the region by 2025 [3].
T2DM is a major independent risk factor for car-
diovascular disease (CVD), the most common cause 
of morbidity and mortality among diabetic patients [4]. 
The increasing incidence of non-communicable diseases 
(NCDs) including diabetes and cardiovascular diseases, 
places a huge burden on Egypt’s healthcare resources 
and about 41 % of all deaths in Egypt are from NCDs [5]. 
Therefore, better understanding of the pathogenesis of 
CVD and T2DM is of great interest for early prediction 
and identification of at-risk patients and for better clini-
cal management.
Modifiable factors such as dyslipidemia, obesity, oxida-
tive stress, smoking, exercise and alcohol intake, as well 
as non-modifiable factors: age, sex, positive family his-
tory and genetic predisposition of the individual, have 
been identified as risk factors for both T2DM and CVD 
[6].
Lipoprotein- related mechanisms have been associated 
with damage to the cardiovascular system  in diabetic 
patients [7]. Apolipoprotein E (ApoE) gene which affects 
the clearance of lipoproteins [8] and, consequently, 
the lipid profile in our body [9] is one of the most stud-
ied candidate genes for T2DM and/or CVD in the last 
decade.
ApoE gene, located on the long arm of chromosome 
19 at position q13.2, is a polymorphic gene with single 
nucleotide polymorphisms (SNPs) at positions 112 and 
158 resulting in three major alleles: ε2, ε3, and ε4, cod-
ing for 3 isoforms: apoE2 (Cys112/Cys158), the most 
common apoE3 (Cys112/Arg158) and apoE4 (Arg112/
Arg158) with 6 possible genotypes: E2/E2, E2/E3, E3/E3, 
E3/E4, E4/E4 and E2/E4 [6, 10].
ApoE isoforms have different effects on the metabolism 
of lipoproteins. Allele ε2 is associated with lower plasma 
levels of LDL cholesterol and lower risk of coronary 
artery disease (CAD) [11], meanwhile, ε4 allele is associ-
ated with higher plasma levels of total cholesterol (TC), 
LDL-C, very low-density lipoprotein cholesterol (VLDL-
C), and greater risk of CAD when compared with ε3 allele 
[12]. Impaired lipid clearance by apoE ε4 is attributed to 
its higher affinity to LDL-R compared to other alleles 
leading to early “receptor occupation” and accumula-
tion of LDL particles which suppress LDL-R synthesis 
resulting in lower clearance of lipoproteins from the body 
through LDL-R [13]. Also, a direct relationship between 
apoE isoforms and premature atherosclerosis has been 
reported [6] and recently apoE ε4 allele has been associ-
ated with the development of both T2DM and CAD [14]. 
The aim of this study is to investigate the association of 
apoE gene polymorphism with T2DM and CVD and its 
effect on plasma lipid levels.
Methods
Subjects
Studied subjects were recruited from the Outpatients 
Clinic of the National Research Centre and the National 
Diabetes and Endocrinology Institute. Data of family 
and medical history, smoking habits and physical activ-
ity was obtained by questionnaire. Physical activity was 
defined as exercise for 2–3 days/week for at least 30 min. 
Clinical examination including measurement of systolic 
blood pressure (SBP) and diastolic blood pressure (DBP) 
was applied. Anthropometric measurements (weight 
and height) were collected and used for BMI calculation 
according to the standard formula BMI  =  weight (kg)/
[height (m)]2. Hypertension was defined as blood pres-
sure above 140/90  mmHg or taking antihypertensive 
drugs. Dyslipidemia was defined as level of total cho-
lesterol (TC)  >200  mg/dL, triglycerides (TG)  >150  mg/
dL, LDL-C >130 mg/dL, HDL-C <40 mg/dL, TC/HDL-C 
ratio >4.0 or under medication of lipid lowering drugs [15]. 
According to the criteria of American Diabetes Associa-
tion [16], studied subjects were classified into 3 groups:
Control group included 84 healthy subjects with fasting 
plasma glucose (FPG)  <100  mg/dL. Exclusion criteria 
were hyperlipidemia, hypertension, CVD or family his-
tory of any form of CVD, diabetes mellitus, hepatic and 
renal diseases, endocrine disease, metabolic disorders, 
autoimmune diseases and those under medication.
T2DM patients without CVD included 100 subjects 
fulfilled the diabetes mellitus diagnostic criteria of 
FPG ≥126 mg/dL or under diabetes medication (oral and/
or insulin) with no history or signs of any CVD. Exclusion 
criteria included renal disease, hepatic disease, endocrine 
disease, metabolic disorders and autoimmune diseases.
T2DM complicated with CVD included 100 subjects diag-
nosed to have diabetes with FPG ≥126  mg/dL or under 
diabetes medication and complicated with any of the 
vascular disease e.g. ischemic heart disease (IHD), mac-
roangiopathy and/or cerebrovascular disease. Exclusion 
criteria included renal disease, hepatic disease, endocrine 
disease, metabolic disorders and autoimmune diseases.
Informed consent was obtained from all subjects and 
the study protocol was approved by the Ethics Commit-
tee of the National Research Centre.
Lipid analysis and biochemical markers
Venous blood samples were collected from all subjects 
after 12 h fast. Total cholesterol (TC), Triglycerides (TG), 
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high density lipoprotein cholestrol (HDL-C), low density 
lipoprotein cholestrol (LDL-C), fasting plasma glucose 
(FPG) were assayed on Roche Diagnostics clinical chem-
istry auto analyzer c311 (Germany). Glycosylated hemo-
globin (HbA1c) was measured by high-performance 
liquid chromatographic (HPLC) method using Agilent 
1100 series HPLC system (Agilent Technologies, Ger-
many). VLDL-C level was calculated using the following 
equation: VLDL-C  =  (TC  −  LDL-C  −  HDL-C). Non-
HDL-C level was calculated by subtracting HDL-C value 
from TC value [17].
ApoE genotyping
Genomic DNA was extracted from 2 ml of whole periph-
eral blood using QIAamp DNA extraction kit (Qiagen 
Hilden, Germany, Cat no. 51304) according to the manu-
facturer’s protocol.
ApoE gene was genotyped using TaqMan® SNP Geno-
typing Assays. SNPs at positions 112 (rs429358) and 158 
(rs7412) determined the encoded alleles, ε2 (rs429358-
T + rs7412-T), ε4 (rs429358-C + rs7412-C) and ε3 allele 
(rs429358-T  +  rs7412-C). All primers and probes were 
designed by Applied Biosystems (Foster City, CA, USA) 
and genotyping analyses were performed on ABI 7500 
Real Time PCR system (Applied Biosystems) according to 
the manufacturer’s protocol. For genotyping quality con-
trol, negative controls were included in all SNPs and 10 % 
of samples were randomly selected and analyzed in dupli-
cates and the concordance rate was 100 %.
Statistical analysis
The collected data and the clinical results have been 
statistically analyzed using IBM SPSS version 20.0 soft-
ware (Statistical Package for Social Science). Quanti-
tative data were expressed as mean values  ±  standard 
deviation (SD). Ranges and frequency of distributions 
were estimated for quantitative variables. Normally dis-
tributed data were compared using Student’s t test for 2 
groups and ANOVA test for more than 2 groups. The sig-
nificance of differences between proportions was tested 
by the Chi square test (χ2). Differences were considered 
significant with p value  <0.05. Allele and genotype dif-
ferences between groups and deviations from Hardy–
Weinberg equilibrium were tested by Chi square test. 
Univariable logistic regression analysis was used to test 
the association between diseases and Apo E gene poly-
morphism and presented as unadjusted odds ratios (OR) 
with confidence interval (95  % CI). Multivariate logistic 
regression analysis was used to determine the risk factors 
for development of diseases with adjustment for potential 
covariates: age, gender, BMI, smoking status and physical 
activity and presented as adjusted ORs.
Results
General characteristics and biochemical variables of the 
study population
The study included 284 subjects classified into 100 
patients with T2DM, 100 patients with T2DM +  CVD, 
and 84 control subjects. Their age ranged from 40 to 
68 years. The frequencies of CVDs in our patients were: 
67 % ischemic heart disease (IHD), 13 % cerebrovascular 
disease, 11 % macroangiopathy, 6 % combined IHD and 
cerebrovascular disease, and 3  % combined macroangi-
opathy and cerebrovascular disease.
A significant age difference was found between control 
subjects and CVD patients (p < 0.0001) implying a higher 
risk of developing CVD with increasing age. Also a sig-
nificant sex difference was found between CVD patients 
and, both, controls (p  =  0.003) and T2DM patients 
(p = 0.01), signifying that male gender is associated with 
higher chances to develop CVD and T2DM. Diabetic 
patients with CVD had lower levels of physical activity 
(p = 0.005) and longer durations of diabetes (p = 0.001) 
when compared to controls and T2DM patients. BMI, 
SBP and DBP were significantly higher in patient groups 
than in controls. Higher frequencies of hypertension 
(p  <  0.0001) and smoking (p  =  0.01) were observed 
among CVD patients when compared to T2DM patients. 
Plasma glucose and HbA1C levels were significantly 
higher in patients compared to controls (p < 0.0001).
Lipid profile data showed a significant association 
between dyslipidemia and CVD in diabetic patients 
(p < 0.0001). Significantly higher levels of TC, TG, LDL-
C, VLDL-C, non HDL-C, TC/HDL-C and lower levels of 
HDL-C were demonstrated in patients compared to con-
trols. CVD patients showed significantly lower levels of 
HDL-C (p = 0.018) and higher levels of TC (p = 0.027), 
VLDL-C (p  =  0.015), non HDL-C (p  =  0.009) than 
T2DM patients. Demographic, clinical and biochemical 
data of enrolled subjects are summarized in Table 1.
ApoE genotype and allele frequencies in patients 
and controls
The genotype distributions of all groups were in Hardy–
Weinberg equilibrium (p  >  0.05). E3/E3 was the most 
common genotype in our subjects. Genotype and allele 
frequencies among studied groups showed significant 
differences (p  =  0.014 and 0.023, respectively). In CVD 
patients, the frequency of E3/E3 genotype was significantly 
lower (p = 0.04), while the frequencies of E3/E4 genotype 
and ε4 allele were significantly higher when compared to 
controls (p  =  0.004 and 0.007, respectively). In T2DM 
patients, though E3/E4 genotype and ε4 allele frequencies 
were higher than in controls, the differences were not sig-
nificant (p = 0.41 and 0.43, respectively) (Fig. 1).
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Table 1 Demographic, clinical and biochemical data of the study population
BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, HbA1c hemoglobin A1C, TC total cholesterol, LDL-C low density lipoprotein cholesterol, 
HDL-C high density lipoprotein cholesterol, VLDL-C very low density lipoprotein cholesterol
* Significant p in comparison between controls and T2DM
** Significant p in comparison between controls and T2DM + CVD
† Significant p in comparison between T2DM and T2DM + CVD






Age (years) 51.8 ± 5.2 50.9 ± 7.5 58.3 ± 7.2**
Sex (male/female) 45/39 57/43 74/26**†
BMI (kg/m2) 23.21 ± 4.62 27.59 ± 4.90* 29.81 ± 5.55**
SBP (mmHg) 115.3 ± 9.6 131.5 ± 19.7* 145.1 ± 22.6**†
DBP (mmHg) 77.6 ± 6.9 79.7 ± 18.0* 90.6 ± 9.7**†
Hypertension (%) – 31.4 94.7†
Smokers (%) 11.1 7.8 15.7†
Physical activity (%) 66.7 54.9 31.6**†
Diabetes duration (years) – 8.4 ± 7.2 13.3 ± 7.4†
Dyslipidemia (%) – 72.5 92.1†
Glucose (mg/dL) 85 ± 9.5 147.1 ± 64.1* 161 ± 66.2**
HbA1c (%) 5.3 ± 0.6 6.4 ± 1.2* 6.6 ± 1.3**
Triglyceride (mg/dL) 118.3 ± 31.1 145.6 ± 72* 164.5 ± 66.2**
TC (mg/dL) 175.7 ± 16 192.1 ± 48.4* 212.7 ± 47.9**†
LDL‑C (mg/dL) 104.7 ± 7 118.22 ± 38.9* 123 ± 43.7**
HDL‑C (mg/dL) 53.9 ± 9.7 49.2 ± 11.2* 43.9 ± 11.8**†
VLDL‑C (mg/dL) 17.1 ± 24.2 29.1 ± 14.4* 39.6 ± 22.9**†
Non‑HDL‑C (mg/dL) 121.14 ± 15.9 147.8 ± 44.9* 162.7 ± 47.7*†



















Fig. 1 Genotypes distribution and alleles’ frequency of ApoE gene polymorphism in patients and controls
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Association of apoE gene polymorphism with T2DM 
and CVD
Univariate analysis to study the association of different 
genotypes and alleles with the risk of T2DM and CVD as 
compared to healthy controls showed that E3/E4 geno-
type associated with 3.6-fold increased risk to develop 
CVD (P  =  0.004) and ε4 allele associated with 3.2-fold 
increased CVD risk (p = 0.007). Although, E3/E4 geno-
type increased the risk for T2DM by 1.5 times, it was of 
no statistical significance (p = 0.41) (Fig. 2).
Association studies for the CVD risk in T2DM 
patients revealed that diabetic patient who carried E3/
E4 genotype were at 2.4-fold increased risk to develop 
CVD (P = 0.02), while ε4 allele carriers were at 2.23-fold 
increased risk (P = 0.02) (Fig. 3).
Multivariate logistic regression analysis after adjust-
ment for other established risk factors: age, male gender, 
BMI, smoking status and physical activity, showed that 
E3/E4 genotype was an independent risk factor for CVD 
(p = 0.009) but not for T2DM (p = 0.28). Allele ε4 was 
an independent risk factor for both T2DM (p  =  0.04) 
and CVD (p  =  0.018) and increased the risk of CVD 
in T2DM patients by 5.9 folds (p =  0.019). As regards 
































Fig. 2 Association of ApoE gene polymorphism with the risk of T2DM (a), CVD (b)
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activity were independent risk factors for CVD, while 
BMI was the only independent risk factor for T2DM 
(Fig. 4). For CVD risk in T2DM patients, age, male gen-
der, BMI, smoking status and physical activity were the 
independent risk factors. Diabetic smokers were 17.5 
times more-at risk to develop CVD than non- smokers 
(p = 0.013) (Fig. 5).
ApoE genotypes and plasma lipids profile
By comparing the plasma lipid profile parameters in the 
E4-bearing genotype in our study i.e. E3/E4 with E3/E3 gen-
otype as a reference, we found that E3/E4 genotype associ-
ated with significantly higher levels of TC and non HDL-C 
in all groups and significantly higher levels of LDL-C in both 


























Fig. 4 Adjusted odds ratio (OR) of the multivariate logistic regression analysis for T2DM and CVD risk
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have higher levels of VLDL-C and lower levels of HDL-C, 
yet the differences were not significant (Table 2).
Discussion
ApoE is a 299-amino acids plasma glycoprotein which 
acts as a high affinity ligand for several hepatic lipopro-
tein receptors such as LDL-R and LDL-related protein 
(LRP1) and is involved in several lipoproteins metabo-
lism, transport and digestion [18]. Dyslipidemia or dys-
lipoproteinemia might strongly contribute in aggravating 
the micro- and macro-vascular  complications  and the 
related accelerated atherosclerosis in diabetic patients 
[7] and recently has been suggested to be associated with 
both T2DM and CAD [14]. Since, different apoE iso-
forms associate with significant variation in lipid profiles 
[19], the coding apoE gene is a candidate for CVD and/or 
diabetes. In this work, we studied the association of apoE 
gene polymorphism with T2DM and CVD and its effect 
on plasma lipid parameters.
ApoE gene polymorphism and risk of diabetes and CVD
To our knowledge this is the first study to investigate 
apoE gene polymorphism in T2DM with and with-
out CVD in our population, E3/E3 was the most com-
mon genotype. Significant higher frequencies of E3/E4 
genotype and ε4 allele were observed among our CVD 
patients. Individuals who carried E3/E4 genotype were 
at 3.6- fold higher risk to develop CVD while ε4 allele 
carriers were at 3.2-fold higher risk. In diabetic patients, 
E3/E4 genotype and ε4 allele increased the CVD risk by 
2.4- and 2.23-folds, respectively. Multivariate regression 

















Fig. 5 Adjusted odds ratio (OR) of the multivariate logistic regression analysis for CVD risk in T2DM patients
Table 2 Lipid profile parameters in apoE E3/E3 vs. E3/E4 genotypes






E3/E3 (n = 66) E3/E4 (n = 7) E3/E3 (n = 80) E3/E4 (n = 12) E3/E3 (n = 65) E3/E4 (n = 25)
TC 171.24 ± 25.15 189.42 ± 8.52** 191.47 ± 51.06 223.30 ± 22.80** 204.55 ± 42.35 221.56 ± 70.37*
TG 114.99 ± 32.08 121.71 ± 31.19 153.78 ± 74.98 145.92 ± 65.05 159.72 ± 61.47 149.08 ± 79.28
HDL‑C 53.14 ± 10.97 50.85 ± 9.24 44 ± 12.52 42.38 ± 11.08 50.52 ± 10.85 48.86 ± 13.49
LDL‑C 109.06 ± 20.40 96.28 ± 4.85 116.72 ± 40.17 151.76 ± 18.85** 121.67 ± 43.16 135 ± 61.85*
VLDL‑C 20 ± 9.6 21 ± 11.8 29.75 ± 14.95 31.15 ± 12.61 32.35 ± 12.16 35.7 ± 23.15
Non‑HDL‑C 118 ± 19.4 139 ± 13** 147.47 ± 46.27 180.92 ± 23.76** 154.03 ± 41.29 170.7 ± 61.77*
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factor for CVD, but not for T2DM, while ε4 allele was an 
independent risk factor for both T2DM and CVD and 
associated with 5.9-fold higher risk of CVD in T2DM 
patients.
Results from previous studies suggest that apoE ε4 
allele has a variable significance in terms of predict-
ing the risk of vascular events in different populations. 
In Finnish population, apoE genotypes were found to 
modulate the risk of coronary heart disease (CHD) and 
atherosclerotic vascular disease in non-insulin depend-
ent diabetes mellitus (NIDDM) [20, 21]. Genotypes E4/
E4 and E3/E4 associated with increased risk for CHD 
in NIDDM patients and the prevalence of CHD disease 
among diabetic patients with genotypes E4/E4 or E3/
E4 was 81 vs. 58  % among patients with genotype E3/
E3, and 53 % among those with genotypes E2/E2 or E3/
E3 [20]. Also, E4-bearing genotypes associated with 
increased risk for macro and micro vascular complica-
tions in NIDDM patients both in men and women, in 
contrast to  E2 phenotype which somehow protected 
from macroangiopathy and associated with lower 
plasma TC and LDL-C concentrations and lower plasma 
lipoprotein (a) levels [21]. In contrast, apo E polymor-
phism, notably, the ε4 allele was not found to influence 
the risk for cardiovascular disease in Italian diabetic 
patients and no significant differences among differ-
ent genotypes were identified [22]. However, in another 
Italian study, apoE ε4 allele was reported as a risk factor 
for CAD and has been associated with low apoE  con-
centrations [23]. In Greek patients with CAD, there was 
no significant association between ε4 allele and risk for 
CAD or myocardial infarction (MI), though a negative 
association of ε2 allele with Ml was observed [24]. Also, 
ε4  allele was not associated with an increased risk for 
CVD or ischemic vascular event (IVE) among Greek 
patients with CVD [25].
Meanwhile, significant association between ApoE 
polymorphism and CAD has been reported in several 
ethnic groups [12, 14, 26–34]. In Chinese study, apoE 
ε4 allele was reported to be associated with the increased 
risk of CAD in T2DM. Diabetic patients who carried 
E3/E4 or  E4/E4 genotypes had higher concentrations of 
serum TC, LDL-C and lipoprotein (a) than patients with 
E2/E2 or E3/E2 genotypes, they also had the highest mor-
tality rate (50 %) during 3–10 years follow-up period [12].
In Thai population, Apo ε4  allele  has been reported as 
an independent risk factor for the development of both 
T2DM and CAD [14]. After adjusting for other risk fac-
tors, E3/E4 carriers showed 2.52-fold higher risk for CAD 
in T2DM patients. Moreover, allele ε4-bearing genotypes 
increased the risk of CAD by 2.32 folds and the risk of 
T2DM by 2.04 folds when compared to controls and the 
risk increased when combined with smoking and/or 
obesity confirming that development and progression of 
diabetes and CAD are multifactorial and no single factor 
can give a satisfactory explanation regarding the disease 
development [14].
In a recent meta-analysis evaluating the association 
of apoE gene polymorphism with atherosclerosis risk 
including subgroup analysis, the overall analysis and sub-
group analysis based on ethnicities showed no significant 
association between apoE polymorphism and risk of ath-
erosclerosis. However, subgroup analysis based on clini-
cal phenotypes of atherosclerosis (clinical and subclinical 
atherosclerosis) showed that ε4 allele associated with 
incidence of clinical atherosclerosis [35].
In our study, age, BMI, male gender and physical activ-
ity were independent risk factors for CVD, while BMI 
was the only independent risk for T2DM. Diabetic smok-
ers were 17.5 times more-at risk to develop CVD than 
non-smokers. Recently, smoking and obesity have been 
reported to be the two major risk factors that can pro-
mote the development of T2DM and CAD or both [14] 
which has been attributed to the enhanced oxidative 
stress that results in decreased insulin secretion and 
decreased uptake by the muscle cells [36]. Oxidative 
stress also increases vascular inflammation and involved 
in the development of CVD with or without combination 
of diabetes [37].
Oxidative stress and vascular complications in diabetes
Hyperglycemia-induced oxidative stress in diabetic 
patients induces endothelial dysfunction which plays a 
central role in the pathogenesis of vascular diseases and 
may also increase pro-inflammatory and pro-coagulant 
factors expression [38]. Lower plasma levels of extracellu-
lar superoxide dismutase (EC-SOD), a major antioxidant 
enzyme, and higher plasma levels of advanced oxidation 
protein products (AOPP), markers of oxidative stress, 
have been detected and associated with myocardial 
infarction in diabetic patients [39].
Also, the anti-atherogenic properties of HDL might be 
affected by hyperglycemia. Glycated HDL has a reduced 
ability to protect against oxidation and in  vitro stud-
ies showed that glycation can both inactivate PON1 (an 
enzyme that accounts for most of the antioxidant effect 
of HDL to prevent oxidation of LDL) and increase lipid 
peroxidation in HDL [40, 41]. Reduced PON-1 activ-
ity and concentration in studies of healthy subjects with 
elevated fasting glucose levels [42] and increased insulin 
resistance [43] support these in vitro data.
In a previous study on serum advanced glycation end 
products (AGEs) and its association with oxidative stress 
and PON-1 activity in T2DM patients, lower enzyme 
activity has been associated with vascular complica-
tions and AGEs showed a significant negative correlation 
Page 9 of 11El‑Lebedy et al. Cardiovasc Diabetol  (2016) 15:12 
with enzyme activity [44]. Apolipoprotein A-1 (apoA-
I) is the major protein component of HDL that plays a 
major role in cholesterol homeostasis and exerts anti-
inflammatory, antioxidant, and anti-atherogenic proper-
ties by stabilizing PON-1 enzyme [45]. In a recent study, 
glycated apoA-I has been reported to be associated with 
decreased activities of serum and HDL-associated PON1 
and PON3 as well as the presence and severity of CAD in 
T2DM patients [46].
Recently, an interaction between the γ-glutamyltransferase-1 
(GGT1) genotype and low serum levels of HDL-C has been 
identified in diabetic micro and macro angiopathy particu-
larly among the G allele carriers, a variant that was associated 
with higher GGT serum levels. Increased pro-oxidant effect of 
GGT by increased LDL-associated GGT and GGT-mediated 
LDL-oxidation, together with coexisting low HDL-C, was sug-
gested to be the mechanism linking GGT to the cardiovascu-
lar events [47].
Effect of apoE genotype on plasma lipids
Our results showed that E3/E4 genotype associated with 
higher levels of TC and non HDL-C in all studied sub-
jects, and with higher levels LDL-C in both T2DM and 
CVD patients highlighting the significance of increased 
LDL-C levels in T2DM and CVD development, in con-
trast to the previous report that non-HDL-C level is 
a strong predictor of CVD risk in T2DM and is particu-
larly indicative of coronary events [48].
Results from previous studies regarding the relation 
between the apoE genotype and plasma lipids profile are 
inconsistent among different ethnic populations. In Indi-
ans, E3/E4 genotype was associated with lower HDL-C 
and higher LDL-C concentrations in CAD patients [49] 
and with higher TG levels in T2DM patients [50]. In Thai 
population, ε4 allele-diabetic carriers showed a signifi-
cantly higher VLDL-C, TG and lower HDL-C levels com-
pared to E3/E3 genotype carriers [14]. In a recent study 
on Kashmiri population, ε4 allele associated with signifi-
cantly higher levels of LDL and TC in CAD patients [34]. 
ApoE ε4 allele associated with increased LDL-C in Tuni-
sian men with T2DM [32] and with higher LDL-C and 
lower HDL-C levels in Spanish women with T2DM [51] 
suggesting that gender might affect the impact of apoE 
gene polymorphism on lipid parameters [14].
Conclusion
Our study indicates that apoE gene polymorphisms asso-
ciate with CVD and identifies apoE ε4 allele as an inde-
pendent risk factor for both T2DM and CVD. Different 
apoE genotypes associate with significant variation in 
plasma lipids profile. Multiple risk factors interact and 
play a role in the development of T2DM and/or CVD. 
Further genetic studies to add information beyond the 
traditional cardiovascular risk factors in T2DM patients 
and to identify risk genotypes will help in early prediction 
and identification of at risk patients.
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